Group 1 - The A-share pharmaceutical sector showed strong performance in the morning session, with notable gains in CRO, biopharmaceuticals, and innovative drugs [1] - Kangchen Pharmaceutical reached the daily limit increase, while Anke Bio surged over 6% [1] - Other stocks such as Kangtai Biological, Zhifei Biological, and Ganli Pharmaceutical also experienced upward movement [1]

Group 1 - The A-share pharmaceutical sector experienced a strong upward trend in early trading, with significant gains in concepts such as CRO, recombinant proteins, and innovative drugs [1] - Companies like Medisi saw an increase of over 16%, while Bid Pharma rose more than 7%, with other stocks like Zhaoyan New Drug, Sunshine Nuohuo, and Nossger also following suit [1] - The National Development and Reform Commission announced that since the 14th Five-Year Plan, 402 new drugs have been added to the national medical insurance drug list [1]

Group 1 - The concepts of CRO, weight loss drugs, and innovative drugs are experiencing a resurgence in the market [1] - Companies such as Puris, which saw a rise of over 14%, and Jizhitang, which hit the daily limit, are leading this trend [1] - Other companies like Saily Medical, Shanghai Yizhong, Yinuosi, and Aosaikan are also witnessing significant gains [1]

Group 1 - The A-share pharmaceutical sector has collectively rebounded, with concepts such as recombinant proteins, CRO, biopharmaceuticals, and innovative drugs showing reduced declines [1] - Jinbo Bio has seen an increase of over 3%, with stocks like Shanghai Laishi, Wantai Bio, and Bid Pharma also experiencing gains [1] - Trump previously announced that drug tariffs could reach as high as 200% [1]

Truth Social just filed for its "Crypto Blue Chip ETF"And it will hold Bitcoin, ETH, SOL, XRP and CROWith a bigger CRO allocation than XRP https://t.co/K9BpseKu4a ...

Group 1 - The ChiNext Index initially increased by 1%, while the Shanghai Composite Index rose by 0.15% [1] - The large healthcare sector experienced a collective rebound, with strong performance in CRO, innovative drugs, monoclonal antibodies, and recombinant proteins [1] - Approximately 3,800 stocks in the market rose, while 1,300 stocks declined, indicating a net outflow of over 2 billion yuan from major funds [1]

Group 1: Macro and Industry Policy Tracking - The report highlights a focus on industrial digital transformation and financial system innovation, with regulatory reforms in the industrial product licensing system to enhance standardization and intelligent management [10][11][12] - The Shenzhen Stock Exchange has introduced standards for "light assets and high R&D investment," improving the inclusivity of the ChiNext board for technology companies [12][10] - In the healthcare sector, policies are being implemented to open medical insurance data for innovative drug development, promoting collaboration among medical, pharmaceutical, and insurance sectors [13][10] - The transportation sector has released a three-year task list for "air-rail intermodal transport," aiming to enhance multi-modal collaboration and information sharing [17][10] Group 2: Asset Price Performance - A-shares showed mixed performance across sectors, with the top five gainers being Steel II (+5.98%), Building Materials II (+4.33%), Pharmaceutical Biology (+4.33%), Banking (+3.78%), and Electrical Equipment (+2.44%) [18][19] - The sectors with the largest declines included Software Services (-1.05%), Semiconductors (-0.89%), Household Products (-0.74%), Business Services (-0.71%), and Transportation (-0.43%) [18][19] Group 3: Popular Concepts Tracking - The top ten gaining concepts this week included CRO (+7.08%), Innovative Drugs (+6.99%), Aquaculture (+6.42%), Rooftop Photovoltaics (+5.85%), and Vitamins (+5.80%) [21][22] - The top ten declining concepts included Selected Airlines Transport (-4.03%), Lithium Battery Cathodes (-2.48%), and Pinduoduo Partners (-2.34%) [21][22]

Market Overview - The three major A-share indices experienced declines, with the Shanghai Composite Index down by 0.21%, the Shenzhen Component down by 0.7%, and the ChiNext Index down by 1.25% [1] Sector Performance - The electricity sector showed resilience, with stocks such as Shaanxi Energy, Huayin Electric, and Shimao Energy hitting the daily limit up [1] - The real estate sector rebounded, with stocks like Chongqing Development and Shahe Shares also reaching the daily limit up [1] - The digital currency concept saw initial gains, with Beijing North achieving two consecutive limit ups [1] - New consumption concepts, including IP economy and ice and snow economy, experienced upward movement, with sectors like lottery, sports, cross-border e-commerce, and cultural media showing early gains [1] - The large pharmaceutical sector faced collective weakness, with concepts such as CRO, recombinant proteins, and biological products declining in early trading [1] - Stocks related to Nvidia and Apple continued to decline for several consecutive days [1]

智通财经7月7日电，市场早盘震荡调整，创业板指领跌。沪深两市半日成交额7718亿，较上个交易日缩 量910亿。盘面上热点较为杂乱，个股涨多跌少，全市场超2900只个股上涨。从板块来看，稳定币概念 股集体走强，京北方等多股涨停。电力股维持强势，华银电力等涨停。地产股震荡反弹，渝开发等涨 停。下跌方面，CPO概念股集体调整，中际旭创等跌超4%。板块方面，中船系、稳定币、电力、房地 产等板块涨幅居前，CRO、CPO、消费电子、脑机接口等板块跌幅居前。截至收盘，沪指跌0.21%，深 成指跌0.7%，创业板指跌1.25%。 午评：创业板指半日跌1.25% 稳定币、电力股逆势走强 ...

Group 1 - The article highlights significant announcements in the stock market from Sunday to Thursday, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, earnings reports, unlocks, and high transfers" [1] - Important announcements are marked in red to assist investors in identifying investment hotspots and preventing various black swan events, providing ample time for analysis and selection of suitable listed companies [1] Group 2 - A company has received an order for a semiconductor mask writing lithography machine and is in discussions with clients regarding solid-state battery collaborations [1] - Another company has secured orders related to humanoid robots and robotic dog cables, with connections to offshore equipment, nuclear power, and data centers [1] - A company in the weight loss drug sector has achieved ton-level production capacity for peptide raw materials, also involved in synthetic biology and CRO (Contract Research Organization) [1]